OKOLICSANYI, STEFANO
 Distribuzione geografica
Continente #
NA - Nord America 4.233
EU - Europa 1.917
AS - Asia 780
SA - Sud America 15
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 5
AF - Africa 4
Totale 6.960
Nazione #
US - Stati Uniti d'America 4.161
IT - Italia 373
DE - Germania 349
CN - Cina 335
SE - Svezia 258
SG - Singapore 232
IE - Irlanda 207
RU - Federazione Russa 173
UA - Ucraina 165
GB - Regno Unito 120
HK - Hong Kong 76
CA - Canada 71
DK - Danimarca 66
AT - Austria 63
IN - India 51
FI - Finlandia 47
VN - Vietnam 32
FR - Francia 27
BE - Belgio 20
TR - Turchia 19
NL - Olanda 17
KR - Corea 14
ES - Italia 8
BR - Brasile 7
IR - Iran 6
CZ - Repubblica Ceca 4
TW - Taiwan 4
AU - Australia 3
CH - Svizzera 3
EU - Europa 3
JP - Giappone 3
NO - Norvegia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BG - Bulgaria 2
CL - Cile 2
CO - Colombia 2
EC - Ecuador 2
MD - Moldavia 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PL - Polonia 2
PT - Portogallo 2
SC - Seychelles 2
TH - Thailandia 2
A1 - Anonimo 1
AR - Argentina 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BO - Bolivia 1
DZ - Algeria 1
GR - Grecia 1
HU - Ungheria 1
ID - Indonesia 1
JO - Giordania 1
LI - Liechtenstein 1
LT - Lituania 1
MA - Marocco 1
ME - Montenegro 1
MX - Messico 1
RO - Romania 1
Totale 6.960
Città #
Ann Arbor 862
Woodbridge 462
Fairfield 339
Houston 292
Chandler 271
Wilmington 230
Ashburn 207
Frankfurt am Main 204
Dublin 200
Singapore 195
Dearborn 166
Jacksonville 157
Cambridge 133
Seattle 132
New York 112
Milan 109
Princeton 81
Hong Kong 76
Santa Clara 70
Nanjing 64
Vienna 62
Shanghai 49
Altamura 39
Lawrence 38
Lachine 26
Tianjin 22
Nanchang 21
Shenyang 20
Dong Ket 18
Guangzhou 18
San Diego 18
Beijing 17
Fremont 16
Helsinki 16
Brussels 15
Ottawa 15
Jinan 14
Boston 13
Andover 12
Boardman 12
Kunming 12
Edmonton 11
Lissone 11
Mountain View 10
Nürnberg 10
Toronto 10
Changsha 8
Falls Church 8
Hangzhou 8
Hebei 8
Jiaxing 8
Los Angeles 7
Ningbo 7
Zhengzhou 7
Busto Arsizio 6
Kiev 6
London 6
Manchester 6
Pune 6
Taizhou 6
Washington 6
Valencia 5
Valmadrera 5
Bergamo 4
Hounslow 4
Indianapolis 4
Montréal 4
Nottingham 4
Nutley 4
Padova 4
Sacramento 4
Segrate 4
Seoul 4
Taipei 4
Verona 4
Chicago 3
Dallas 3
Hefei 3
Lanzhou 3
Legnano 3
Munich 3
Newtyle 3
Phoenix 3
Saint-Maurice-en-Gourgois 3
Tappahannock 3
Wenzhou 3
Aachen 2
Assèmini 2
Auburn Hills 2
Auckland 2
Bangkok 2
Beerse 2
Benevento 2
Bonndorf 2
Chongqing 2
Copenhagen 2
Daejeon 2
Delhi 2
Edinburgh 2
Foggia 2
Totale 5.109
Nome #
Impact of multidisciplinary team approach to liver tumors: 5-Years experience 377
Impact of multidisciplinary team approach to liver tumors in a tertiary center: 5-years experience 345
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 296
Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma 252
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 237
Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study 213
Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice 202
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 199
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 196
P0811 : Sofosbuvir-based direct-acting antivirals treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 194
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 193
Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions 193
Health Related Quality of Life in the Major Liver Conditions 189
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 187
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 181
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 180
The impact of liver disease on the health-related quality of life 179
Health related quality of life in chronic liver diseases 178
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 177
Characteristics of patients with Chronic Hepatitis C who have failed past treatment or who have never been treated: How much room left for Interferon? 175
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 174
PGI36 Relationship Between Clinical Severity and Health Related Quality of Life in Chronic Liver Diseases 171
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 170
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 170
Sofosbuvir-based all-oral treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 168
Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib 162
PGI31 Health Care Indicators to Measure Quality of Care in Patients with Liver Diseases 160
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 158
Liver-allocation policies for patients affected by HCC in Europe 157
Management of treatment-naïve chronic hepatitis C genotype 1 patients: A cost-effectiveness analysis of treatment options 156
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 152
Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis 152
Sorafenib paradoxically activates the raf/mek/erk signaling in mice with polycystic liver disease (pld) caused by conditional deletion of polycystin-2 151
Management of chronic hepatitis C (Chc) genotype 1 treatment-naïve patients in an era of rising opportunities and costs: A cost-effectiveness analysis 147
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 147
Surgical management of hepatocellular carcinoma within and beyond BCLC indications in a middle volume center 142
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 135
Difference in health related quality of life of chronic liver diseases and general population 109
Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? 107
Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite. 106
Totale 7.337
Categoria #
all - tutte 22.914
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.914


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020677 0 0 0 0 0 0 214 114 137 103 90 19
2020/2021929 46 55 109 111 93 73 59 85 77 83 59 79
2021/2022551 51 59 72 57 16 41 19 41 26 37 38 94
2022/20231.054 106 369 88 90 56 139 21 73 68 3 31 10
2023/2024647 21 27 15 49 58 213 127 24 40 6 5 62
2024/2025644 86 160 115 47 123 59 54 0 0 0 0 0
Totale 7.337